問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Ophthalmology

更新時間：2023-09-19

張祐誠Chang, Yo-Chen
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

Recruiting Trial

7Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

張祐誠

List

9Cases

2021-11-01 - 2031-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-02-03 - 2029-12-31

Others

Active
A PHASE IIIB/IV, MULTICENTER, RANDOMIZED, OPEN-LABEL, TWO-ARM STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND DURABILITY OF FARICIMAB ADMINISTERED UP TO EVERY 24 WEEKS IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (CONSTANCE)

  • Condition/Disease

    Evaluate the efficacy of intravitreal (IVT) faricimab in the study eye for each treatment group, based on the mean change from baseline in best-corrected visual acuity (BCVA) at Weeks 44, 48, and 52.

  • Test Drug

    Injection

Participate Sites
3Sites

Recruiting3Sites

2021-07-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-08-20 - 2024-08-07

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2020-10-30 - 2025-07-28

Phase III

Completed
A 96-week, two-arm, randomized, single-masked, multi-center, phase III study assessing the efficacy and safety of brolucizumab 6 mg compared to panretinal photocoagulation laser in patients with proliferative diabetic retinopathy(CONDOR)

  • Condition/Disease

    patients with proliferative diabetic

  • Test Drug

    RTH258 (Brolucizumab)

Participate Sites
2Sites

Recruiting2Sites

2024-12-01 - 2032-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-11-01 - 2031-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-05-01 - 2021-08-20

Phase III

To determine if treatment with aflibercept 8 mg (HD) at intervals of 12 or 16 weeks provides non-inferior BCVA change compared to aflibercept 2 mg every 8 weeks in participants with nAMD

  • Condition/Disease

    NAMD

  • Test Drug

    BAY 86-5321

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2021-08-15 - 2024-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB